Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | NLRP3 | Q96P20 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10180506 | 0.89 | AKR1C3 (0.51) | AKR1C3DNMT3ALMNAMAPTNPC1 | |
| SCHEMBL1153992 | 0.89 | AKR1C3 (0.59) | AKR1C3DNMT3AMRGPRX4PTGER1LMNA | |
| SCHEMBL4013089 | 0.89 | PTGER4 (0.55) | AKR1C3DNMT3APTGER4LMNAMAPT | |
| SCHEMBL1154704 | 0.89 | AKR1C3 (0.50) | AKR1C3DNMT3APTGER4MRGPRX4PTGER1 | |
| SCHEMBL1154192 | 0.88 | DNMT3A (0.53) | AKR1C3DNMT3APTGER4MRGPRX4PTGER1 | |
| SCHEMBL1153664 | 0.87 | PTGER4 (0.59) | AKR1C3DNMT3APTGER4MRGPRX4PTGER1 | |
| SCHEMBL1154081 | 0.85 | AKR1C3 (0.52) | AKR1C3DNMT3APTGER4MRGPRX4PTGER1 | |
| SCHEMBL1154066 | 0.85 | AKR1C3 (0.55) | AKR1C3DNMT3APTGER4PTGER1LMNA | |
| SCHEMBL1154527 | 0.84 | AKR1C3 (0.57) | AKR1C3DNMT3APTGER4MRGPRX4PTGER1 | |
| SCHEMBL1154552 | 0.84 | KMT2A (0.61) | AKR1C3DNMT3APTGER1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | claimed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | claimed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | claimed |
| EP-2215065-A1 | CCR10 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | claimed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | claimed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-8299123-B2 | CCR10 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-30 | — | — | US | disclosed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | disclosed |
| EP-2215065-B1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-07-11 | — | — | EP | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| US-20110039851-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-17 | — | — | US | disclosed |
| EP-2215065-A1 | CCR10 ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
| WO-2009052078-A1 | CCR10 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039851-A1 | CCR10 ANTAGONISTS | CCR10, CCR1, CCR4 | AKR1C3 680/4885DNMT3A 4688/4885PTGER4 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.